Long-term follow-up of111 In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer
Purpose: To evaluate the long-term failure patterns in patients who underwent an111 In-capromab pendetide (ProstaScint) scan as part of their pretreatment assessment for a rising prostate-specific antigen (PSA) level after prostatectomy and subsequently received local radiotherapy (RT) to the prosta...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 67; no. 3; pp. 834 - 840 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: To evaluate the long-term failure patterns in patients who underwent an111 In-capromab pendetide (ProstaScint) scan as part of their pretreatment assessment for a rising prostate-specific antigen (PSA) level after prostatectomy and subsequently received local radiotherapy (RT) to the prostate bed. Methods: Fifty-eight patients were referred for evaluation of a rising PSA level after radical prostatectomy. All patients had negative findings for metastatic disease after abdominal/pelvis imaging with CT and isotope bone scans. All patients underwent a capromab pendetide scan, and the sites of uptake were noted. All patients were treated with local prostate bed RT (median dose 66.6 Gy). Results: Of the 58 patients, 20 had biochemical failure (post-RT PSA level >0.2 ng/mL or a rise to greater than the nadir PSA), including 6 patients with positive uptake outside the bed (positive elsewhere). The 4-year biochemical relapse-free survival (bRFS) rates for patients with negative (53%), positive in the prostate bed alone (45%), or positive elsewhere (74%) scan findings did not differ significantly ( p = 0.51). The positive predictive value of the capromab pendetide scan in detecting disease outside the bed was 27%. The capromab pendetide scan status had no effect on bRFS. Those with a pre-RT PSA level of <1 ng/mL had improved bRFS ( p = 0.003). Conclusion: The capromab pendetide scan has a low positive predictive value in patients with positive elsewhere uptake and the 4-year bRFS was similar to that for those who did not exhibit positive elsewhere uptake. Therefore, patients with a postprostatectomy rising PSA level should considered for local RT on the basis of clinicopathologic factors. |
---|---|
AbstractList | Purpose: To evaluate the long-term failure patterns in patients who underwent an111 In-capromab pendetide (ProstaScint) scan as part of their pretreatment assessment for a rising prostate-specific antigen (PSA) level after prostatectomy and subsequently received local radiotherapy (RT) to the prostate bed. Methods: Fifty-eight patients were referred for evaluation of a rising PSA level after radical prostatectomy. All patients had negative findings for metastatic disease after abdominal/pelvis imaging with CT and isotope bone scans. All patients underwent a capromab pendetide scan, and the sites of uptake were noted. All patients were treated with local prostate bed RT (median dose 66.6 Gy). Results: Of the 58 patients, 20 had biochemical failure (post-RT PSA level >0.2 ng/mL or a rise to greater than the nadir PSA), including 6 patients with positive uptake outside the bed (positive elsewhere). The 4-year biochemical relapse-free survival (bRFS) rates for patients with negative (53%), positive in the prostate bed alone (45%), or positive elsewhere (74%) scan findings did not differ significantly ( p = 0.51). The positive predictive value of the capromab pendetide scan in detecting disease outside the bed was 27%. The capromab pendetide scan status had no effect on bRFS. Those with a pre-RT PSA level of <1 ng/mL had improved bRFS ( p = 0.003). Conclusion: The capromab pendetide scan has a low positive predictive value in patients with positive elsewhere uptake and the 4-year bRFS was similar to that for those who did not exhibit positive elsewhere uptake. Therefore, patients with a postprostatectomy rising PSA level should considered for local RT on the basis of clinicopathologic factors. |
Author | Dillehay, Gary, M.D Wagner, Robert, M.D Khan, Usman, B.S Mohideen, Najeeb, M.D Lo, Simon S., M.D Campbell, Steven, M.D Nagda, Suneel N., M.D Flanigan, Robert, M.D |
Author_xml | – sequence: 1 fullname: Nagda, Suneel N., M.D – sequence: 2 fullname: Mohideen, Najeeb, M.D – sequence: 3 fullname: Lo, Simon S., M.D – sequence: 4 fullname: Khan, Usman, B.S – sequence: 5 fullname: Dillehay, Gary, M.D – sequence: 6 fullname: Wagner, Robert, M.D – sequence: 7 fullname: Campbell, Steven, M.D – sequence: 8 fullname: Flanigan, Robert, M.D |
BookMark | eNqlkE1OwzAQhb0oEi1wAxazhEWCnaCgbtggEEgskMo-mjqT1CGxLY_bqqflKjjl5wKs5kdvvvc0CzGzzpIQl0rmSqrqps9NH9za54WUVS6XuSyqmZjLspJZmQSnYsHcSymVurudi89XZ7ssUhihdcPg9tnWg2uVUvBiM40-uBHX4Mk2FE1DcPUWHEdcaWPjNbBGC8jgA8VAGEeyMc1MzMfWWPAYTWoZ9hsH24QJnQPGYYcdQcDGuLihgP6QAgQIho3tEm8yiZSxJ21aowFtNB0lszaFPd5pHP50OrrxG_C7gZRMUzgXJy0OTBc_9UzcPz2-PzxnlIadoVDrwdiJ9UEH4t5tg026WtVc1LJeTX-b3iYrWSyXZVH-G_AFfaSPoA |
ContentType | Journal Article |
Copyright | Elsevier Inc. |
Copyright_xml | – notice: Elsevier Inc. |
DOI | 10.1016/j.ijrobp.2006.09.026 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 840 |
ExternalDocumentID | 1_s2_0_S0360301606029932 |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 1RT 1~5 29J 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAWTL AAXUO ABEFU ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ADBBV ADMUD ADPAM ADVLN AENEX AEVXI AFCTW AFFNX AFJKZ AFRHN AFTJW AGRDE AHHHB AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY DU5 EBS EFJIC EJD F5P FDB FEDTE FGOYB FIRID G-2 GBLVA HED HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LX3 M41 MO0 NQ- O9- OC~ OO- R2- RIG RNS ROL RPZ SAE SDG SEL SES SEW SSZ UDS UV1 X7M XH2 XPP Z5R ZGI ~S- |
ID | FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S03603016060299323 |
ISSN | 0360-3016 |
IngestDate | Tue Oct 15 22:55:24 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Capromab pendetide Recurrence Salvage radiotherapy ProstaScint Prostate cancer |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-elsevier_clinicalkeyesjournals_1_s2_0_S03603016060299323 |
ParticipantIDs | elsevier_clinicalkeyesjournals_1_s2_0_S0360301606029932 |
PublicationCentury | 2000 |
PublicationDate | 2007 |
PublicationDateYYYYMMDD | 2007-01-01 |
PublicationDate_xml | – year: 2007 text: 2007 |
PublicationDecade | 2000 |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationYear | 2007 |
SSID | ssj0001174 |
Score | 3.7486696 |
Snippet | Purpose: To evaluate the long-term failure patterns in patients who underwent an111 In-capromab pendetide (ProstaScint) scan as part of their pretreatment... |
SourceID | elsevier |
SourceType | Publisher |
StartPage | 834 |
SubjectTerms | Hematology, Oncology and Palliative Medicine Radiology |
Title | Long-term follow-up of111 In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0360301606029932 |
Volume | 67 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3da9swEMBFm8LYy9gn6764hz1sGBknduz6ZdCVjrI0YSwty5uRLDsftHaxnRX2z-5f2cmSbaXpYMuLCUJSZJ9_p_P57kzIe-HjNhx6MfW54BS3gJQecdejvvAccRS7qRvLN7rjiX926X2dDWd7-zMjamldcTv-dW9eyS5SxTaUq8yS_Q_JtpNiA_5G-eIRJYzHf5LxeZ7NqdStVorizG_p-gaNP9QriD2NGSrHa8at-iu31VLU1uQ3meXBkGhZbyC0SqkEWSlLBRgh5221TqurvFpat4u8_mpuMc-tkl39lNE-BRNLncOlIj9RZ6j89rxOVaIyk1NGI1koQVn4U3-UXI6Td0fTL67yazVB0yLD0WIdOrzqwu0776VR80LOpk3fLG7Tb3iXiaP8N-3jw4TNBVMxSVmSXFmTWkWO7Tb6eZwv8HopjTxhqyThdzqc1x7mKd7oqB7vjh4tlFf5stTu5c_2dMO7Ehjq1_Vxh3JUJmizV_iBwYRrKP7GJattCFWCamt7Up6Slb1cFTm_0a_CQtsZ3FMN_PRk1KflwHboVC5FrsTxHbQetD94s0p4PyoHkRNtdd0nB4MgHHo9cnA8-v5j1FopfV2hvDnLJq20jn3cXp9hqxn218Vj8kg_OMGxouAJ2Uuyp-TBWIeGPCO_WxighQFqGMCAAVoY4IOBwkeQIAArwQQBOhBgmUEDAiAIoEEADQKYIOACClAgwBYIoEGAGgTQIMAGCPUETQsoEJ6TT19OL07OaHOBoiapGbfhpNQ0lNHfROS-IL0sz5KXBEIeOkIwfGaTpQf9gCeB8MWwn6QDHntpfEiCHf_k1c4jX5OH6n2GdDu-Ib2qWCdv0RCv-Dt9T_0BobPtTg |
link.rule.ids | 315,786,790,4043,27954,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+follow-up+of111+In-capromab+pendetide+%28ProstaScint%29+scan+as+pretreatment+assessment+in+patients+who+undergo+salvage+radiotherapy+for+rising+prostate-specific+antigen+after+radical+prostatectomy+for+prostate+cancer&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Nagda%2C+Suneel+N.%2C+M.D&rft.au=Mohideen%2C+Najeeb%2C+M.D&rft.au=Lo%2C+Simon+S.%2C+M.D&rft.au=Khan%2C+Usman%2C+B.S&rft.date=2007&rft.issn=0360-3016&rft.volume=67&rft.issue=3&rft.spage=834&rft.epage=840&rft_id=info:doi/10.1016%2Fj.ijrobp.2006.09.026&rft.externalDBID=ECK1-s2.0-S0360301606029932&rft.externalDocID=1_s2_0_S0360301606029932 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03603016%2FS0360301607X0484X%2Fcov150h.gif |